James Crowe | Director
Vanderbilt Vaccine Center

Dr. James Crowe is Director of the Vanderbilt Vaccine Center and the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology at Vanderbilt. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. He is an elected member of the National Academy of Medicine, National Academy of Inventors, and other major professional organizations. His team discovered the antibodies that formed the basis for EVUSHELD™ (tixagevimab + cilgavimab) for COVID-19 prevention, which was approved in Europe, authorized in the US, and used in millions of individuals in 70 countries. The group has been recognized widely as a leader in antibody sciences, for instance as the Best Academic Research Team, 11th Annual Vaccine Industry Excellence Awards, World Vaccine Congress, recipient of the Merck Future Insight Prize for Pandemic Preparedness, and large-scale research grants and contracts from NIH and DoD, including the DARPA Pandemic Prevention Program (P3).